Long-Term Follow-up Study for Patients Previously Treated With JCAR015
Completed
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Genetic: JCAR015
- Registration Number
- NCT02813252
- Lead Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Brief Summary
This study will provide long-term follow-up for patients who have received treatment with JCAR015 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of JCAR015 for evaluation of delayed adverse events, presence of persisting JCAR015 vector sequences, and survival.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description JCAR015-treated JCAR015 Patients who received previous treatment with JCAR015
- Primary Outcome Measures
Name Time Method Proportion of patients with adverse events Every year for up to 15 years post-treatment Proportion of patients with detectable JCAR015 vector sequences during first 5 years post-treatment Every 6 months for the first 5 years post-treatment Proportion of patients with detectable JCAR015 vector sequences between 5 and 15 years post-treatment Every year from 5 years post-treatment to up to 15 years post-treatment Survival Up to 15 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
🇺🇸Baltimore, Maryland, United States
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Northwestern University
🇺🇸Chicago, Illinois, United States